Warning signs for Xencor
Data on the group’s lead project, the PD-1 x CTLA-4 bispecific vudalimab, are far from emphatic.
Janux gives conditionally acting therapeutics hope
Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.
Revolution pushes home its pan-KRAS advantage
Not long after starting phase 1, RMC-6236 could be in pivotal trials this year.
Arcus makes its HIF2α pitch
After living in the shadow of Arcus’s TIGIT project, casdatifan might soon come into its own.
Safety remains in focus for Cogent’s bezuclastinib
An “optimised formulation” of bezuclastinib looks promising, but the safety question remains open.
Deal analysis part one – the bad
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
The new normal in US oncology approvals
Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?
Deal analysis part two – the good
A look at big oncology deals since 2016 finds outright success stories hard to come by.
Mesothelin lives on
Work targeting mesothelin, and some other antigens that have hitherto disappointed, continues.
Lack of overall survival doesn't stop Flaura2
Approval on the basis of Flaura2 is part of a double success for Astra's Tagrisso, which has also scored in Laura.
